

ANTIGENICS INC /DE/  
Form 8-K  
November 16, 2006

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

November 16, 2006

Date of Report (Date of earliest event reported)

---

**ANTIGENICS INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**  
(State or other jurisdiction

of incorporation)

**000-29089**  
(Commission File Number)

**06-1562417**  
(IRS Employer

Identification No.)

**630 Fifth Avenue, Suite 2100**

**New York, NY 10111**  
(Address of principal executive offices)

**212-994-8200**

**10111**  
(Zip Code)

(Registrant's telephone number, including area code)

## Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01** Regulation FD Disclosure

On November 16, 2006, Antigenics Inc. announced that preliminary data from a Phase 1/2 investigator-sponsored trial of the company's investigational cancer vaccine Oncophage® (vitespen; formerly HSPPC-96) as a treatment for recurrent glioma were presented at the Immunotherapy Task Force Meeting, held at the Society of Neuro-Oncology's 11<sup>th</sup> Annual Scientific Meeting. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

**Item 9.01** Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated November 16, 2006

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTIGENICS INC.**

Date: November 16, 2006

By: /s/ Garo H. Armen  
Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer

EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
99.1	Press Release dated November 16, 2006